You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas has reached more than 172 million patients in 103 locations around the world with our products. Our on-market portfolio includes transformative therapies in oncology, ophthalmology, urology, immunology, and women's health.
The products listed on this website are Astellas' main products globally. Availability may vary by location or region, and products may be marketed under different brand names, indications, dosages, and strengths. These medications are typically available only by prescription from healthcare professionals.
Japan product information and related documents can be accessed here: Medicines available in Japan
Product information and related documents for all other locations can be accessed here: Medicines by Location
enfortumab vedotin
For the treatment of locally advanced or metastatic urothelial cancer
avacincaptad pegol intravitreal solution
For the treatment of geographic atrophy secondary to age-related macular degeneration
fezolinetant
For the treatment of moderate to severe vasomotor symptoms associated with/due to menopause
zolbetuximab
For the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive
gilteritinib
For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation
enzalutamide
For the treatment of advanced prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR)
mirabegron
For the treatment of overactive bladder (OAB)
tacrolimus
For use with other adjuvants and medicines to help prevent organ rejection in people who have had a kidney, liver, heart, or lung transplant
Our current product portfolio supports a diverse range of therapeutic areas including oncology, ophthalmology, urology, immunology, and women's health.